Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Analysts at Scotiabank
Scotiabank initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report published on Wednesday, MarketBeat Ratings reports. The brokerage issued a sector outperform rating and a $305.00 target price on the biopharmaceutical company’s stock. Other research analysts have also issued reports about the stock. Evercore ISI boosted their target […]
More Stories
Oklahoma Bank Shut Down by Regulator in 2nd Bank Failure of the Year
By Naveen Athrappully The First National Bank of Lindsay was forced to cease operations after the Office of the Comptroller...
Royal Bank of Canada Increases Wave Life Sciences (NASDAQ:WVE) Price Target to $15.00
Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price target boosted by research analysts at Royal Bank of...
U.S. Bancorp (NYSE:USB) Shares Sold by Koss Olinger Consulting LLC
Koss Olinger Consulting LLC cut its stake in shares of U.S. Bancorp (NYSE:USB – Free Report) by 6.5% during the...
Tecnoglass (NASDAQ:TGLS) Sets New 52-Week High Following Analyst Upgrade
Tecnoglass Inc. (NASDAQ:TGLS – Get Free Report) reached a new 52-week high during trading on Monday after Robert W. Baird...
Stacks (STX) Reaches 24 Hour Trading Volume of $75.32 Million
Stacks (STX) traded 3.6% lower against the US dollar during the 1 day period ending at 10:00 AM E.T. on...
BKV (NYSE:BKV) Receives New Coverage from Analysts at Evercore ISI
Research analysts at Evercore ISI initiated coverage on shares of BKV (NYSE:BKV – Get Free Report) in a report released...